ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Metachromatic Leukodystrophy (MLD) Treatment Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-24D9219
Home | Market Reports | Health| Pharmacy
Global Metachromatic Leukodystrophy MLD Treatment Market Insights and Forecast to 2028
BUY CHAPTERS

Global Metachromatic Leukodystrophy (MLD) Treatment Market Research Report 2025

Code: QYRE-Auto-24D9219
Report
September 2025
Pages:70
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
ArmaGen Inc.
GlaxoSmithKline PLC
Recursion Pharmaceuticals Inc
REGENXBIO
Takeda

Metachromatic Leukodystrophy (MLD) Treatment Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Metachromatic Leukodystrophy (MLD) Treatment Market

Metachromatic Leukodystrophy (MLD) Treatment Market

The global market for Metachromatic Leukodystrophy (MLD) Treatment was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Metachromatic Leukodystrophy (MLD) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Metachromatic Leukodystrophy (MLD) Treatment.
The Metachromatic Leukodystrophy (MLD) Treatment market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Metachromatic Leukodystrophy (MLD) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Metachromatic Leukodystrophy (MLD) Treatment manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Metachromatic Leukodystrophy (MLD) Treatment Market Report

Report Metric Details
Report Name Metachromatic Leukodystrophy (MLD) Treatment Market
CAGR 5%
Segment by Type
  • AGT-183
  • DUOC-01
  • GSK-2696274
  • Others
Segment by Application
  • Hospital
  • Clinic
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company ArmaGen Inc, GlaxoSmithKline Plc, Recursion Pharmaceuticals Inc, RegenxBio Inc, Takeda
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Metachromatic Leukodystrophy (MLD) Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Metachromatic Leukodystrophy (MLD) Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Metachromatic Leukodystrophy (MLD) Treatment Market report?

Ans: The main players in the Metachromatic Leukodystrophy (MLD) Treatment Market are ArmaGen Inc, GlaxoSmithKline Plc, Recursion Pharmaceuticals Inc, RegenxBio Inc, Takeda

What are the Application segmentation covered in the Metachromatic Leukodystrophy (MLD) Treatment Market report?

Ans: The Applications covered in the Metachromatic Leukodystrophy (MLD) Treatment Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Metachromatic Leukodystrophy (MLD) Treatment Market report?

Ans: The Types covered in the Metachromatic Leukodystrophy (MLD) Treatment Market report are AGT-183, DUOC-01, GSK-2696274, Others

Recommended Reports

Rare Disease Therapies

Neurological Disorders

Blood & Immune Diseases

1 Metachromatic Leukodystrophy (MLD) Treatment Market Overview
1.1 Product Definition
1.2 Metachromatic Leukodystrophy (MLD) Treatment by Type
1.2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Market Value Comparison by Type (2024 VS 2031)
1.2.2 AGT-183
1.2.3 DUOC-01
1.2.4 GSK-2696274
1.2.5 Others
1.3 Metachromatic Leukodystrophy (MLD) Treatment by Application
1.3.1 Global Metachromatic Leukodystrophy (MLD) Treatment Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Metachromatic Leukodystrophy (MLD) Treatment Market Size Estimates and Forecasts
1.4.1 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue 2020-2031
1.4.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales 2020-2031
1.4.3 Global Metachromatic Leukodystrophy (MLD) Treatment Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Metachromatic Leukodystrophy (MLD) Treatment Market Competition by Manufacturers
2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Manufacturers (2020-2025)
2.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Metachromatic Leukodystrophy (MLD) Treatment Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Metachromatic Leukodystrophy (MLD) Treatment, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Metachromatic Leukodystrophy (MLD) Treatment, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Metachromatic Leukodystrophy (MLD) Treatment, Product Type & Application
2.7 Global Key Manufacturers of Metachromatic Leukodystrophy (MLD) Treatment, Date of Enter into This Industry
2.8 Global Metachromatic Leukodystrophy (MLD) Treatment Market Competitive Situation and Trends
2.8.1 Global Metachromatic Leukodystrophy (MLD) Treatment Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Metachromatic Leukodystrophy (MLD) Treatment Players Market Share by Revenue
2.8.3 Global Metachromatic Leukodystrophy (MLD) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Metachromatic Leukodystrophy (MLD) Treatment Market Scenario by Region
3.1 Global Metachromatic Leukodystrophy (MLD) Treatment Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region: 2020-2031
3.2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region: 2020-2025
3.2.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region: 2026-2031
3.3 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region: 2020-2031
3.3.1 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region: 2020-2025
3.3.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region: 2026-2031
3.4 North America Metachromatic Leukodystrophy (MLD) Treatment Market Facts & Figures by Country
3.4.1 North America Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2020-2031)
3.4.3 North America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Metachromatic Leukodystrophy (MLD) Treatment Market Facts & Figures by Country
3.5.1 Europe Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2020-2031)
3.5.3 Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Market Facts & Figures by Region
3.6.1 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Region (2020-2031)
3.6.3 Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Metachromatic Leukodystrophy (MLD) Treatment Market Facts & Figures by Country
3.7.1 Latin America Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2020-2031)
3.7.3 Latin America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Market Facts & Figures by Country
3.8.1 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2020-2031)
3.8.3 Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2020-2031)
4.1.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2020-2025)
4.1.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Type (2026-2031)
4.1.3 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Type (2020-2031)
4.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2020-2031)
4.2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2020-2025)
4.2.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Type (2026-2031)
4.2.3 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Type (2020-2031)
4.3 Global Metachromatic Leukodystrophy (MLD) Treatment Price by Type (2020-2031)
5 Segment by Application
5.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2020-2031)
5.1.1 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2020-2025)
5.1.2 Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Application (2026-2031)
5.1.3 Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Application (2020-2031)
5.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2020-2031)
5.2.1 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2020-2025)
5.2.2 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Application (2026-2031)
5.2.3 Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Application (2020-2031)
5.3 Global Metachromatic Leukodystrophy (MLD) Treatment Price by Application (2020-2031)
6 Key Companies Profiled
6.1 ArmaGen Inc
6.1.1 ArmaGen Inc Company Information
6.1.2 ArmaGen Inc Description and Business Overview
6.1.3 ArmaGen Inc Metachromatic Leukodystrophy (MLD) Treatment Sales, Revenue and Gross Margin (2020-2025)
6.1.4 ArmaGen Inc Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio
6.1.5 ArmaGen Inc Recent Developments/Updates
6.2 GlaxoSmithKline Plc
6.2.1 GlaxoSmithKline Plc Company Information
6.2.2 GlaxoSmithKline Plc Description and Business Overview
6.2.3 GlaxoSmithKline Plc Metachromatic Leukodystrophy (MLD) Treatment Sales, Revenue and Gross Margin (2020-2025)
6.2.4 GlaxoSmithKline Plc Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio
6.2.5 GlaxoSmithKline Plc Recent Developments/Updates
6.3 Recursion Pharmaceuticals Inc
6.3.1 Recursion Pharmaceuticals Inc Company Information
6.3.2 Recursion Pharmaceuticals Inc Description and Business Overview
6.3.3 Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy (MLD) Treatment Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio
6.3.5 Recursion Pharmaceuticals Inc Recent Developments/Updates
6.4 RegenxBio Inc
6.4.1 RegenxBio Inc Company Information
6.4.2 RegenxBio Inc Description and Business Overview
6.4.3 RegenxBio Inc Metachromatic Leukodystrophy (MLD) Treatment Sales, Revenue and Gross Margin (2020-2025)
6.4.4 RegenxBio Inc Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio
6.4.5 RegenxBio Inc Recent Developments/Updates
6.5 Takeda
6.5.1 Takeda Company Information
6.5.2 Takeda Description and Business Overview
6.5.3 Takeda Metachromatic Leukodystrophy (MLD) Treatment Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Takeda Metachromatic Leukodystrophy (MLD) Treatment Product Portfolio
6.5.5 Takeda Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Metachromatic Leukodystrophy (MLD) Treatment Industry Chain Analysis
7.2 Metachromatic Leukodystrophy (MLD) Treatment Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Metachromatic Leukodystrophy (MLD) Treatment Production Mode & Process Analysis
7.4 Metachromatic Leukodystrophy (MLD) Treatment Sales and Marketing
7.4.1 Metachromatic Leukodystrophy (MLD) Treatment Sales Channels
7.4.2 Metachromatic Leukodystrophy (MLD) Treatment Distributors
7.5 Metachromatic Leukodystrophy (MLD) Treatment Customer Analysis
8 Metachromatic Leukodystrophy (MLD) Treatment Market Dynamics
8.1 Metachromatic Leukodystrophy (MLD) Treatment Industry Trends
8.2 Metachromatic Leukodystrophy (MLD) Treatment Market Drivers
8.3 Metachromatic Leukodystrophy (MLD) Treatment Market Challenges
8.4 Metachromatic Leukodystrophy (MLD) Treatment Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
ArmaGen Inc.
GlaxoSmithKline PLC
Recursion Pharmaceuticals Inc
REGENXBIO
Takeda
List of Tables
 Table 1. Global Metachromatic Leukodystrophy (MLD) Treatment Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Metachromatic Leukodystrophy (MLD) Treatment Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Metachromatic Leukodystrophy (MLD) Treatment Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Metachromatic Leukodystrophy (MLD) Treatment Sales (K Pcs) of Key Manufacturers (2020-2025)
 Table 5. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Metachromatic Leukodystrophy (MLD) Treatment Average Price (USD/Pcs) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Metachromatic Leukodystrophy (MLD) Treatment, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Metachromatic Leukodystrophy (MLD) Treatment, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Metachromatic Leukodystrophy (MLD) Treatment, Product Type & Application
 Table 12. Global Key Manufacturers of Metachromatic Leukodystrophy (MLD) Treatment, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Metachromatic Leukodystrophy (MLD) Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metachromatic Leukodystrophy (MLD) Treatment as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Metachromatic Leukodystrophy (MLD) Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region (2020-2025) & (K Pcs)
 Table 18. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Region (2020-2025)
 Table 19. Global Metachromatic Leukodystrophy (MLD) Treatment Sales by Region (2026-2031) & (K Pcs)
 Table 20. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Region (2026-2031)
 Table 21. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Region (2020-2025)
 Table 23. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Region (2026-2031)
 Table 25. North America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2020-2025) & (K Pcs)
 Table 27. North America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2026-2031) & (K Pcs)
 Table 28. North America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2020-2025) & (K Pcs)
 Table 32. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2026-2031) & (K Pcs)
 Table 33. Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Region (2020-2025) & (K Pcs)
 Table 37. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales by Region (2026-2031) & (K Pcs)
 Table 38. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2020-2025) & (K Pcs)
 Table 42. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2026-2031) & (K Pcs)
 Table 43. Latin America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2020-2025) & (K Pcs)
 Table 47. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales by Country (2026-2031) & (K Pcs)
 Table 48. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Metachromatic Leukodystrophy (MLD) Treatment Sales (K Pcs) by Type (2020-2025)
 Table 51. Global Metachromatic Leukodystrophy (MLD) Treatment Sales (K Pcs) by Type (2026-2031)
 Table 52. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Type (2020-2025)
 Table 53. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Type (2026-2031)
 Table 54. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Type (2020-2025)
 Table 57. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Type (2026-2031)
 Table 58. Global Metachromatic Leukodystrophy (MLD) Treatment Price (USD/Pcs) by Type (2020-2025)
 Table 59. Global Metachromatic Leukodystrophy (MLD) Treatment Price (USD/Pcs) by Type (2026-2031)
 Table 60. Global Metachromatic Leukodystrophy (MLD) Treatment Sales (K Pcs) by Application (2020-2025)
 Table 61. Global Metachromatic Leukodystrophy (MLD) Treatment Sales (K Pcs) by Application (2026-2031)
 Table 62. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Application (2020-2025)
 Table 63. Global Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Application (2026-2031)
 Table 64. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Application (2020-2025)
 Table 67. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Application (2026-2031)
 Table 68. Global Metachromatic Leukodystrophy (MLD) Treatment Price (USD/Pcs) by Application (2020-2025)
 Table 69. Global Metachromatic Leukodystrophy (MLD) Treatment Price (USD/Pcs) by Application (2026-2031)
 Table 70. ArmaGen Inc Company Information
 Table 71. ArmaGen Inc Description and Business Overview
 Table 72. ArmaGen Inc Metachromatic Leukodystrophy (MLD) Treatment Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 73. ArmaGen Inc Metachromatic Leukodystrophy (MLD) Treatment Product
 Table 74. ArmaGen Inc Recent Developments/Updates
 Table 75. GlaxoSmithKline Plc Company Information
 Table 76. GlaxoSmithKline Plc Description and Business Overview
 Table 77. GlaxoSmithKline Plc Metachromatic Leukodystrophy (MLD) Treatment Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 78. GlaxoSmithKline Plc Metachromatic Leukodystrophy (MLD) Treatment Product
 Table 79. GlaxoSmithKline Plc Recent Developments/Updates
 Table 80. Recursion Pharmaceuticals Inc Company Information
 Table 81. Recursion Pharmaceuticals Inc Description and Business Overview
 Table 82. Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy (MLD) Treatment Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 83. Recursion Pharmaceuticals Inc Metachromatic Leukodystrophy (MLD) Treatment Product
 Table 84. Recursion Pharmaceuticals Inc Recent Developments/Updates
 Table 85. RegenxBio Inc Company Information
 Table 86. RegenxBio Inc Description and Business Overview
 Table 87. RegenxBio Inc Metachromatic Leukodystrophy (MLD) Treatment Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 88. RegenxBio Inc Metachromatic Leukodystrophy (MLD) Treatment Product
 Table 89. RegenxBio Inc Recent Developments/Updates
 Table 90. Takeda Company Information
 Table 91. Takeda Description and Business Overview
 Table 92. Takeda Metachromatic Leukodystrophy (MLD) Treatment Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
 Table 93. Takeda Metachromatic Leukodystrophy (MLD) Treatment Product
 Table 94. Takeda Recent Developments/Updates
 Table 95. Key Raw Materials Lists
 Table 96. Raw Materials Key Suppliers Lists
 Table 97. Metachromatic Leukodystrophy (MLD) Treatment Distributors List
 Table 98. Metachromatic Leukodystrophy (MLD) Treatment Customers List
 Table 99. Metachromatic Leukodystrophy (MLD) Treatment Market Trends
 Table 100. Metachromatic Leukodystrophy (MLD) Treatment Market Drivers
 Table 101. Metachromatic Leukodystrophy (MLD) Treatment Market Challenges
 Table 102. Metachromatic Leukodystrophy (MLD) Treatment Market Restraints
 Table 103. Research Programs/Design for This Report
 Table 104. Key Data Information from Secondary Sources
 Table 105. Key Data Information from Primary Sources
 Table 106. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Metachromatic Leukodystrophy (MLD) Treatment
 Figure 2. Global Metachromatic Leukodystrophy (MLD) Treatment Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Metachromatic Leukodystrophy (MLD) Treatment Market Share by Type: 2024 & 2031
 Figure 4. AGT-183 Product Picture
 Figure 5. DUOC-01 Product Picture
 Figure 6. GSK-2696274 Product Picture
 Figure 7. Others Product Picture
 Figure 8. Global Metachromatic Leukodystrophy (MLD) Treatment Market Value by Application (2020-2031) & (US$ Million)
 Figure 9. Global Metachromatic Leukodystrophy (MLD) Treatment Market Share by Application: 2024 & 2031
 Figure 10. Hospital
 Figure 11. Clinic
 Figure 12. Others
 Figure 13. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Metachromatic Leukodystrophy (MLD) Treatment Market Size (2020-2031) & (US$ Million)
 Figure 15. Global Metachromatic Leukodystrophy (MLD) Treatment Sales (2020-2031) & (K Pcs)
 Figure 16. Global Metachromatic Leukodystrophy (MLD) Treatment Average Price (USD/Pcs) & (2020-2031)
 Figure 17. Metachromatic Leukodystrophy (MLD) Treatment Report Years Considered
 Figure 18. Metachromatic Leukodystrophy (MLD) Treatment Sales Share by Manufacturers in 2024
 Figure 19. Global Metachromatic Leukodystrophy (MLD) Treatment Revenue Share by Manufacturers in 2024
 Figure 20. Global 5 and 10 Largest Metachromatic Leukodystrophy (MLD) Treatment Players: Market Share by Revenue in Metachromatic Leukodystrophy (MLD) Treatment in 2024
 Figure 21. Metachromatic Leukodystrophy (MLD) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 22. Global Metachromatic Leukodystrophy (MLD) Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 23. North America Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Country (2020-2031)
 Figure 24. North America Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Country (2020-2031)
 Figure 25. U.S. Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Canada Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. Europe Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Country (2020-2031)
 Figure 28. Europe Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Country (2020-2031)
 Figure 29. Germany Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. France Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. U.K. Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Italy Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Russia Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Region (2020-2031)
 Figure 35. Asia Pacific Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Region (2020-2031)
 Figure 36. China Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Japan Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. South Korea Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. India Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Australia Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Taiwan Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Indonesia Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Thailand Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Malaysia Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Philippines Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Latin America Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Country (2020-2031)
 Figure 47. Latin America Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Country (2020-2031)
 Figure 48. Mexico Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Brazil Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Argentina Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Sales Market Share by Country (2020-2031)
 Figure 52. Middle East and Africa Metachromatic Leukodystrophy (MLD) Treatment Revenue Market Share by Country (2020-2031)
 Figure 53. Turkey Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Saudi Arabia Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. UAE Metachromatic Leukodystrophy (MLD) Treatment Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 56. Global Sales Market Share of Metachromatic Leukodystrophy (MLD) Treatment by Type (2020-2031)
 Figure 57. Global Revenue Market Share of Metachromatic Leukodystrophy (MLD) Treatment by Type (2020-2031)
 Figure 58. Global Metachromatic Leukodystrophy (MLD) Treatment Price (USD/Pcs) by Type (2020-2031)
 Figure 59. Global Sales Market Share of Metachromatic Leukodystrophy (MLD) Treatment by Application (2020-2031)
 Figure 60. Global Revenue Market Share of Metachromatic Leukodystrophy (MLD) Treatment by Application (2020-2031)
 Figure 61. Global Metachromatic Leukodystrophy (MLD) Treatment Price (USD/Pcs) by Application (2020-2031)
 Figure 62. Metachromatic Leukodystrophy (MLD) Treatment Value Chain
 Figure 63. Channels of Distribution (Direct Vs Distribution)
 Figure 64. Bottom-up and Top-down Approaches for This Report
 Figure 65. Data Triangulation
 Figure 66. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano Dimension

SIMILAR REPORTS

Global Globoid Cell Leukodystrophy Treatment Market Research Report 2024
Global Neurologic Disorder Treatment Drug Market Research Report 2024
Global Juvenile Macular Degeneration Treatment Market Research Report 2024
Global Sickle Cell Disease Diagnosis and Treatment Market Research Report 2025
Global Myelodysplastic Syndrome Treatment Market Research Report 2024
Global Waldenstrom s Macroglobulinemia Treatment Market Research Report 2024
Neurodegenerative Disease Treatment Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Retinitis Pigmentosa Treatment Market Research Report 2024
Global Hemoglobinopathies Drugs Market Research Report 2024
Global Myelodysplastic Syndrome Drug Market Research Report 2025
Global B Cell Chronic Lymphocytic Leukemia Treatment Market Research Report 2024
Adrenomyeloneuropathy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Genetic Disease Diagnosis Market Research Report 2024
Hemoglobinopathy Treatment Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Sickle Cell Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Retinal Disorder Treatment Market Research Report 2024
Global Becker Muscular Dystrophy Drug Market Research Report 2024
Primary Immunodeficiency Diseases Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Small Lymphocytic Lymphoma Therapy Market Research Report 2025
Relapsing Multiple Sclerosis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global GLP-1 Targeted Peptide Weight Loss Drugs Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-19A18322
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Stimulant-Free Fat Burners Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3E3525
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Test Boosters Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-35T3049
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Salsalate Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-33Y1801
Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions